ALDX: Aldeyra Therapeutics, Inc.
2022-01-11 08:00:00
Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®
ALDX: Aldeyra Therapeutics, Inc.
2021-08-04 08:00:00
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa
Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease
Statistical Significance of Reproxalap Over Vehicle Achieved for Ocular Redness, an FDA-Approvable Sign, and Clinical Symptoms of Ocular Dryness and Discomfort
Acute Improvement in Ocular Redness and Symptom Scores...
too much consolidation in this chart for a entry, no real trend or signs of a big breakout coming anytime soon. has been 5 years of sideways action and theres nothing stopping it from doing another 5! be careful if theirs calls on it ! very risky here imo, gl <3
Here is a method I have learnt of that makes a ton of sense. Most use a a percentage of their portfolio money per trade to manage risk. This way here makes trades consistent and takes the 'too much/too little' effect out of the picture. Set an amount of money that you are willing to lose on each trade. Stick to it and use the formula. Also try to find a pattern...
Sentiment has been very positive in ALDEYRA THERAPEUTICS having already released positive results for other pipeline drugs. On may 1st phase 2 results for its new Dry Eye Syndrome drug will be presented and optimism is high on the rumor mill. The current price target by 7 analysts covering the name is $31 which is considerable higher than current levels....
